Warts Therapeutics
1. Veregen patent expiration
Treatment: Treatment of genital warts
VEREGEN IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10434059 | ANI PHARMA | Medicament for the treatment of viral skin and tumour diseases |
Nov, 2022
(3 years ago) | |
| US5795911 | ANI PHARMA | Composition for treating Condyloma acuminata |
Oct, 2020
(5 years ago) | |
| US5968973 | ANI PHARMA | Method for treating hyperplasia |
Apr, 2017
(8 years ago) | |
| US9770406 | ANI PHARMA | Medicament for the treatment of viral skin and tumour diseases |
Jul, 2025
(7 months ago) | |
| US7858662 | ANI PHARMA | Medicament for the treatment of viral skin and tumour diseases |
Oct, 2026
(7 months from now) | |
Drugs and Companies using SINECATECHINS ingredient
Market Authorisation Date: 31 October, 2006
Dosage: OINTMENT
More Information on Dosage
VEREGEN family patents
2. Ycanth patent expiration
Treatment: Topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older; Topical treatment of skin lesions caused by an infection with molluscum contagiosum in adult and pe...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12233042 | VERRICA | Treatment of cutaneous disorders |
Aug, 2038
(12 years from now) | |
| US11147790 | VERRICA | Treatment of cutaneous disorders |
Aug, 2038
(12 years from now) | |
| US11052064 | VERRICA | Compositions, methods and systems for the treatment of cutaneous disorders |
May, 2035
(9 years from now) | |
| US12290651 | VERRICA | Devices and methods for the treatment of body surface disorders |
Feb, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 21, 2028 |
Drugs and Companies using CANTHARIDIN ingredient
NCE-1 date: 22 July, 2027
Market Authorisation Date: 21 July, 2023
Dosage: SOLUTION
More Information on Dosage
YCANTH family patents